Journal of Clinical Nephrology and Therapeutics

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Short Communication - Journal of Clinical Nephrology and Therapeutics (2025) Volume 9, Issue 1

Unraveling kidney disease at the cellular level: The role of single-cell RNA sequencing

David Kavanagh >*

Department of Kidney Diseases and Hypertension, Johns Hopkins University, USA

*Corresponding Author:
David Kavanagh
Department of Kidney Diseases and Hypertension, Johns Hopkins University, USA
Institute of Nephrology Research
USA
E-mail: david@kavanagh.edu

Received:02-Feb-2024,Manuscript No. AACNT-24-161909; Editor assigned:03-Feb-2024,PreQC No. AACNT-24-161909(PQ); Reviewed:16-Feb-2024,QC No. AACNT-24-161909; Revised:20-Feb-2024,Manuscript No. AACNT-24-161909(R); Published:27-Feb-2024,DOI: 10.35841/aacnt-9.1.246

Citation: Kavanagh D. Unraveling kidney disease at the cellular level: The role of single-cell RNA sequencing. J Clini Nephrol. 2025; 9(1):246

Visit for more related articles at Journal of Clinical Nephrology and Therapeutics

Introduction

Kidney disease is a growing global health concern, affecting millions of individuals worldwide. Understanding the molecular mechanisms underlying kidney disease is crucial for developing targeted therapies and improving patient outcomes. Traditional bulk RNA sequencing has provided valuable insights into gene expression patterns; however, it lacks the resolution to capture cellular heterogeneity. Single-cell RNA sequencing (scRNA-seq) has emerged as a revolutionary technique that enables the study of gene expression at the level of individual cells, offering unprecedented insights into kidney disease pathophysiology [1].

scRNA-seq is a powerful technology that allows researchers to analyze gene expression profiles at the single-cell level. Unlike bulk RNA sequencing, which averages gene expression across a population of cells, scRNA-seq identifies distinct cellular subpopulations within tissues. This technique has proven to be instrumental in uncovering the complex cellular composition of the kidney, identifying novel cell types, and elucidating disease mechanisms that were previously unrecognized [2].

The kidney consists of multiple specialized cell types, each playing a crucial role in maintaining renal function. In kidney diseases such as chronic kidney disease (CKD) and acute kidney injury (AKI), specific cell populations undergo alterations that contribute to disease progression. scRNA-seq enables researchers to dissect these cellular changes, identifying disease-specific biomarkers and therapeutic targets [3].

One of the most significant contributions of scRNA-seq in kidney research is the discovery of previously unknown cell populations. Studies using this technology have identified rare and transitional cell types involved in fibrosis, inflammation, and regeneration. Understanding these novel cell populations provides new insights into disease progression and potential regenerative therapies [4].

Kidney fibrosis is a hallmark of progressive renal disease, leading to irreversible damage and organ failure. scRNA-seq has revealed how different kidney cell types, including fibroblasts and immune cells, contribute to fibrotic processes. By analyzing cell-specific gene expression, researchers can pinpoint key molecular pathways driving fibrosis and inflammation, paving the way for more precise therapeutic interventions [5].

The ability to profile gene expression at a single-cell resolution holds immense potential for precision medicine in nephrology. By identifying patient-specific molecular signatures, scRNA-seq allows for the development of targeted therapies tailored to an individual's disease profile. This personalized approach enhances treatment efficacy and reduces the risk of adverse effects, ultimately improving patient outcomes [6].

Diabetic kidney disease (DKD) is a leading cause of end-stage renal disease. scRNA-seq has provided novel insights into the cellular and molecular changes occurring in the kidneys of diabetic patients. It has identified early markers of disease progression and potential therapeutic targets, offering hope for early intervention and improved disease management [7].

scRNA-seq is also transforming the field of kidney transplantation by providing insights into immune rejection and graft survival. By analyzing immune cell populations in transplanted kidneys, researchers can identify early signs of rejection, leading to better immunosuppressive strategies and improved transplant outcomes [8].

Despite its potential, scRNA-seq faces several challenges, including high costs, technical complexities, and data interpretation difficulties. However, continuous advancements in sequencing technology and bioinformatics are addressing these limitations, making scRNA-seq more accessible for widespread research and clinical applications in nephrology [9, 10].

Conclusion

Single-cell RNA sequencing has revolutionized kidney disease research by providing an unprecedented view of cellular heterogeneity and disease mechanisms. This technology has uncovered novel cell populations, revealed critical insights into fibrosis and inflammation, and opened new avenues for precision medicine. As scRNA-seq continues to evolve, it holds immense promise for transforming the diagnosis, treatment, and management of kidney diseases, ultimately improving patient care and outcomes.

References

  1. Johansen KL, Chertow GM, Jin C, et al. Significance of frailty among dialysis patients. J Am Soc Nephrol. 2007;18(11):2960-7.

    2. Indexed at, Google Scholar, Cross Ref

  2. Kutner NG. Promoting functioning and well-being in older CKD patients: review of recent evidence. Int Urol Nephrol. 2008;40(4):1151-8.

    3. Indexed at, Google Scholar, Cross Ref

  3. Odden MC. Physical functioning in elderly persons with kidney disease. Adv Chronic Kidney Dis. 2010;17(4):348-57.

    4. Indexed at, Google Scholar, Cross Ref

  4. Cook WL, Jassal SV. Functional dependencies among the elderly on hemodialysis. Kidney Int. 2008;73(11):1289-95.

    5. Indexed at, Google Scholar, Cross Ref

  5. Rosansky SJ, Eggers P, Jackson K, et al. Early start of hemodialysis may be harmful. Arch Intern Med. 2011;171(5):396-403.

    6. Indexed at, Google Scholar, Cross Ref

  6. Grant C, Bayne C. Ureterocele Causing Bladder Outlet Obstruction.J Pediatr. 2018;198:319.

    7. Indexed at, Google Scholar, Cross Ref

  7. McLean RH, Gearhart JP, Jeffs R. Neonatal obstructive uropathy.Pediatr Nephrol. 1988;2(1):48-55.

    8. Indexed at, Google Scholar, Cross Ref

  8. El Imam M, Omran M, Nugud F, et al. Obstructive uropathy in Sudanese patients.Saudi J Kidney Dis Transplant. 2006;17(3):415.

    9. Indexed at, Google Scholar, Cross Ref

  9. Matsusaka T, Miyazaki Y, Ichikawa I. The renin angiotensin system and kidney development.Ann Rev Physiol. 2002;64(1):551-61.

    10. Google Scholar, Cross Ref

  10. Clarkson MR, Giblin L, O'Connell FP, et al. Acute interstitial nephritis: clinical features and response to corticosteroid therapy. Nephrol Dial Transplant. 2004;19(11):2778-83.

    11. Indexed at, Google scholar, Cross Ref

Get the App